Vipul Drugs Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 30-07-2024
- Paid Up Capital ₹ 1.73 Cr
as on 30-07-2024
- Company Age 32 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 14.50 Cr
as on 30-07-2024
- Revenue -99.95%
(FY 2023)
- Profit 60.70%
(FY 2023)
- Ebitda 76.30%
(FY 2023)
- Net Worth -4.79%
(FY 2023)
- Total Assets -0.34%
(FY 2023)
About Vipul Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.73 Cr.
The company has closed loans amounting to ₹14.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Samir Mehta and Vipul Mehta serve as directors at the Company.
- CIN/LLPIN
U22330MH1991PTC064375
- Company No.
064375
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Dec 1991
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Vipul Drugs Private Limited offer?
Vipul Drugs Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Infective API.
Who are the key members and board of directors at Vipul Drugs?
Board Members(2)
Financial Performance and Corporate Structure Insights of Vipul Drugs.
Vipul Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 99.95% decrease. The company also saw a substantial improvement in profitability, with a 60.7% increase in profit. The company's net worth dipped by a decrease of 4.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vipul Drugs?
In 2023, Vipul Drugs had a promoter holding of 87.92% and a public holding of 12.08%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Standard Chartered Bank Creation Date: 12 Mar 2010 | ₹5.50 Cr | Satisfied |
The Greater Bombay Co-Op Bank Ltd Creation Date: 21 Feb 2003 | ₹1.00 Cr | Satisfied |
The Grater Bank Creation Date: 12 Feb 2001 | ₹5.00 M | Satisfied |
How Many Employees Work at Vipul Drugs?
Unlock and access historical data on people associated with Vipul Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vipul Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vipul Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
